NDA 022043 · Janssen Lp
Invega
Paliperidone · Oral
Last checked: Nov 20, 2026Latest source record: Apr 27, 2007 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2007
Apr 27, 2007
Approved uses
1
Original approval plus efficacy supplements
Registered trials
186
60 Phase 3, 3 recruiting
FAERS reports
23,466
11,599 serious, 845 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
4 products under this application
- INVEGA · PALIPERIDONE 12MG · TABLET, EXTENDED RELEASE, ORAL · Prescription
- INVEGA · PALIPERIDONE 6MG · TABLET, EXTENDED RELEASE, ORAL · Prescription
- INVEGA · PALIPERIDONE 9MG · TABLET, EXTENDED RELEASE, ORAL · Prescription
- INVEGA · PALIPERIDONE 3MG · TABLET, EXTENDED RELEASE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Paliperidone" as an intervention, any sponsor and status, largest first.
- An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended Release (ER) in Participants With SchizophreniaPivotal-lookingCompleted
Janssen-Cilag International NVJohnson & Johnson (Janssen) (JNJ)
NCT00460512 · 1,814 participants · Start Apr 25, 2007 · Primary completion Jan 22, 2009
Drug: Paliperidone ER · For: Schizophrenia
Sites: Antwerp, Belgium; Bertrix, Belgium; Dave, Belgium · 231 sites in all
- The Treatment Efficacy of Combination Atypical Antipsychotics With Sertraline in Patients With SchizophreniaPivotal-lookingCompleted
Beijing HuiLongGuan HospitalAcademic, hospital or other
NCT04076371 · 1,640 participants · Start Jan 2012 · Primary completion Dec 2018
Drug: olanzapine-sertraline combination; only olanzapine and 6 more · For: Schizophrenia
- Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With SchizophreniaPivotal-lookingCompleted
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT01515423 · 1,429 participants · Start May 2012 · Primary completion Feb 2015
Drug: PP3M 175 mg eq.; PP3M 263 mg eq. and 7 more · For: Schizophrenia
Sites: Little Rock, Arkansas; Glendale, California; Long Beach, California · 174 sites in all
- Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With SchizophreniaPivotal-lookingCompleted
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
NCT00589914 · 1,221 participants · Start Mar 2007 · Primary completion Jun 2009
Drug: RISPERDAL CONSTA; Paliperidone palmitate · For: Schizophrenia
Sites: Birmingham, Alabama; Little Rock, Arkansas; Cerritos, California · 82 sites in all
- Safety, Efficacy and Tolerability Study of Paliperidone Extended-Release (ER) in Participants With SchizophreniaPivotal-lookingCompleted
Janssen PharmaceuticaJohnson & Johnson (Janssen) (JNJ)
NCT01662648 · 1,117 participants · Start Jun 2007 · Primary completion Apr 2008
Drug: Paliperidone ER · For: Schizophrenia
- Paliperidone Palmitate Flexible Dosing in SchizophreniaPivotal-lookingCompleted
Janssen-Cilag International NVJohnson & Johnson (Janssen) (JNJ)
NCT01281527 · 1,044 participants · Start Nov 2010 · Primary completion Nov 2012
Drug: Paliperidone Palmitate · For: Schizophrenia
Sites: Salzburg, Austria; Brussels, Belgium; Dave, Belgium · 127 sites in all
- Efficacy and Safety of AVE1625 as a Co-treatment With Antipsychotic Therapy in SchizophreniaPivotal-lookingTerminated
SanofiSanofi (SNY)
NCT00439634 · 873 participants · Start Feb 2007 · Primary completion Sep 2009
Drug: AVE1625; placebo · For: Schizophrenia
Sites: Bridgewater, New Jersey; Laval, Canada
- A Study of Paliperidone Palmitate 6-Month FormulationPivotal-lookingCompleted
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT03345342 · 841 participants · Start Nov 20, 2017 · Primary completion May 8, 2020
Drug: PP6M; PP3M 350 mg eq. and 2 more · For: Schizophrenia
Sites: Rogers, Arkansas; Anaheim, California; Costa Mesa, California · 138 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- injury4,330
- gynaecomastia3,666
- drug ineffective1,795
- abnormal weight gain1,662
- off label use1,565
- weight increased1,390
- hyperprolactinaemia1,272
- galactorrhoea1,060
- sedation762
- dyskinesia717
- dystonia715
- treatment noncompliance684
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2007 | 696 |
| 2008 | 743 |
| 2009 | 650 |
| 2010 | 524 |
| 2011 | 687 |
| 2012 | 783 |
| 2013 | 652 |
| 2014 | 966 |
| 2015 | 2,359 |
| 2016 | 4,208 |
| 2017 | 3,453 |
| 2018 | 910 |
| 2019 | 847 |
| 2020 | 814 |
| 2021 | 812 |
| 2022 | 932 |
| 2023 | 924 |
| 2024 | 801 |
| 2025 | 1,024 |
| 2026 | 681 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Invega (Paliperidone)
2024 spending
$2.3M
Beneficiaries
704
4,179 claims
Per beneficiary
$3,336
$13.75 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $122,657,282 |
| 2021 | $84,143,307 |
| 2022 | $25,750,207 |
| 2023 | $5,169,576 |
| 2024 | $2,348,551 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis.
Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. · Lancet 2019 · Research Support, Non-U.S. Gov't, Systematic Review
- Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.
Leucht S, Cipriani A, Spineli L, et al. · Lancet 2013 · Comparative Study, Meta-Analysis
- Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia.
Leucht S, Crippa A, Siafis S, et al. · Am J Psychiatry 2020 · Meta-Analysis
- Mood stabilizers and/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta-analysis of randomized controlled trials.
Kishi T, Ikuta T, Matsuda Y, et al. · Mol Psychiatry 2021 · Network Meta-Analysis, Research Support, Non-U.S. Gov't
- Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis.
Schneider-Thoma J, Chalkou K, Dörries C, et al. · Lancet 2022 · Systematic Review, Network Meta-Analysis
- Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials.
Kishi T, Ikuta T, Matsuda Y, et al. · Mol Psychiatry 2022 · Systematic Review, Research Support, Non-U.S. Gov't
Sponsor: Johnson & Johnson (Janssen)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.